Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022214 | 0.81 | NCF1 (0.46) | KMT2ARAD52RXFP1ALDH1A1CA12 | |
| SCHEMBL21444532 | 0.81 | ALDH1A1 (0.41) | KMT2ARAD52RXFP1ALDH1A1HTT | |
| SCHEMBL25190301 | 0.80 | KMT2A (0.39) | KMT2ARAD52RXFP1ALDH1A1HTT | |
| SCHEMBL238377 | 0.78 | ALDH1A1 (0.43) | KMT2AALDH1A1HTTCA12CA1 | |
| SCHEMBL4027973 | 0.77 | ALDH1A1 (0.50) | KMT2AALDH1A1HTTPRMT6TRPV1 | |
| SCHEMBL18876369 | 0.77 | ALDH1A1 (0.38) | KMT2ARAD52RXFP1ALDH1A1HTT | |
| SCHEMBL4029065 | 0.77 | ALDH1A1 (0.50) | KMT2AALDH1A1HTTPRMT6TRPV1 | |
| SCHEMBL4023577 | 0.77 | ALDH1A1 (0.50) | KMT2AALDH1A1HTTPRMT6TRPV1 | |
| SCHEMBL21593841 | 0.76 | ALDH1A1 (0.38) | KMT2ARAD52RXFP1ALDH1A1HTT | |
| SCHEMBL9832077 | 0.74 | RAB9A (0.46) | ALDH1A1HTTCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660455-B1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LAB (US) | 2008-10-15 | — | — | EP | disclosed |
| US-6933311-B2 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2005-08-23 | — | — | US | disclosed |
| US-20050113576-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES | 2005-05-26 | — | — | US | disclosed |
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | KMT2A 2965/4885RAD52 3216/4885RXFP1 81/4885 |
| US-20050113576-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, TMEM109, VIPR1 | KMT2A 3095/4885RAD52 2946/4885RXFP1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.